On March 26, 2007, SkyePharma Plc announced that the refinancing and the disposal of its injectable business based in San Diego, California had been completed. The disposal constituted a Class 1 transaction for the purposes of Listing Rules. The restructuring, announced on January 9, 2007, also involved a US$68 million loan facility, a US$28 million share issue and related EGM.
SkyePharma is an official listed UK pharmaceutical, biotechnology and drug delivery public company.
June Paddock and Michael Kashis advised SkyePharma in these transactions.